Reading an Orange Book Listing the Way a Litigator Would
The listing tells you what the patentee thinks it owns. That is not the same as what it can enforce.
An Orange Book entry is an assertion, not an adjudication — and the difference is where most ANDA disputes actually live.
Three things to check first
- Use codes. They frame the carve-out fight before anyone files.
- Expiry versus exclusivity. They are different clocks and they routinely disagree.
- Listing dates. A patent listed late tells its own story.
Read together, they usually predict the shape of the litigation better than the claims do.
More insights
Patexia Insight 254: Rankings of Leading ANDA Litigation Attorneys
ANDA litigation remains one of the most demanding areas of patent law, where outcomes often hinge on the experience and judgment of individual attorneys. In disputes that determine when a generic drug can enter the market, the role of lead counsel is…
Patexia Insight 246: What the Latest Data Reveals About ANDA Litigation Trends
Abbreviated New Drug Application (ANDA) litigation remains one of pharma’s most contested arenas. With market exclusivity and billions in annual sales on the line, each case influences competition, pricing, and the speed at which patients see…
Patexia Insight 243: Patent Litigation Trends and Insights from the First Half of 2025
Over the past several years, patent litigation has gone through its share of ups and downs. Shifting legal standards, evolving strategies by patent owners and defendants, and broader economic factors have all played a role in defining the volume and nature…